The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Open accessAbstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF. Methods: This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40 mg, 80 mg, 160 mg, or 320 mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12 weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers. Measurements and Main Results: Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62/89 [69.7%] and 21/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12 weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo. Conclusions: Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers. Clinical trial registered with www.clinicaltrials.gov (NCT04396756).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In rats pretreated with intratracheal silencing MMP7 mRNA, bleomycin induced fibrosis (through the mechanism of MMP7 overexpression) was reduced, leading to improved lung function with reduced fibrosis compared to control [91].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [91]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationRaghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957 · cited 1×
“Idiopathic pulmonary fi brosis (IPF) is a rare and progressive disease characterized by altered lung structure and function due to excessive extracellular matrix deposition, with resulting symptoms of progressive cough, exertional dyspnea, and impaired quality of life (1 – 7).”
BackgroundSelf-citationPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154 · cited 2×
“Both drugs have long-term tolerability issues; pirfenidone is associated with nausea and photosensitivity (12, 14, 19, 20), and nintedanib is associated with diarrhea (10, 21).”
BackgroundSelf-citationLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157 · cited 2×
“Gastrointestinal adverse events, including diarrhea, are common adverse reactions in patients treated with nintedanib or pirfenidone (10, 12 – 14 , 16 ).”
BackgroundResultSelf-citationRaghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716 · cited 1×
“Median life expectancy for untreated patients with IPF is approximately 3 – 4years (2, 8, 9).”
BackgroundAcellular Normal and Fibrotic Human Lung Matrices as a Culture System for In Vitro Investigation
Booth, A. J., Hadley, R., Cornett, A. M., Dreffs, A. A., Matthes, S. A., Tsui, J. L., Weiss, K., Horowitz, J. C., Fiore, V. F., Barker, T. H., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0754oc · Cited by 665
Global incidence and prevalence of idiopathic pulmonary fibrosis
Maher, T. M., Bendstrup, E., Dron, L., Langley, J., Smith, G., Khalid, J. M., Patel, H., & Kreuter, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01791-z · Cited by 612
Self-citation
Research works printed but not linked: 5
- Wuyts, 2023, Late breaking abstract—Safety, tolerability and antifibrotic activity of bexotegrast: phase 2a. INTEGRIS-IPF study (NCT04396756), Eur Respir J, 62, OA1423
- Lancaster, 2023, PLN-74809 shows favorable safety and tolerability and indicates antifibrotic activity in a phase 2a study for the treatment of idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 207, A2777
- Cosgrove, 2022, PLN-74809, a dual-selective inhibitor of αvβ6 and αvβ1, is well tolerated in over 280 healthy participants, Am J Respir Crit Care Med, 205, A2437
- Mooney, 2022, PLN-74809, a dual-selective inhibitor of integrins αvβ6 and αvβ1, shows dose-dependent target engagement in the lungs of patients with idiopathic pulmonary fibrosis (IPF), Am J Respir Crit Care Med, 205, A5254
- Cosgrove, 2022, PLN-74809, an oral, dual-selective αvβ6/αvβ1 inhibitor in phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), sustainably reduces transforming growth factor-beta (TGF-β) activity in the lungs of healthy participants with once-daily dosing, Am J Respir Crit Care Med, 205, A5251
Cited by
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 149
“Nerandomilast, a phosphodiesterase 4B (PDE4B) inhibitor, and bexotegrast, a dual inhibitor of the integrins avβ6 and avβ1, inhibit fibroblast proliferation and myofibroblast differentiation, and nerandomilast also has anti-inflammatory activity 226,227,229 .”
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 121
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy
Sharip, A., & Kunz, J. (2025) · Cells · doi:10.3390/cells14040266 · Cited by 69
“To date, a favorable safety profile and efficacy have been demonstrated in these trials [158–162].”
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
PI3K/Akt in IPF: untangling fibrosis and charting therapies
Bhatt, J., Ghigo, A., & Hirsch, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1549277 · Cited by 40
Metadata
- Authors
- Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., Kim, G. H. J., Jurek, M., Decaris, M., Clark, A., Turner, S., Barnes, C. N., Achneck, H. E., Cosgrove, G. P., Lefebvre, É. A., & Flaherty, K. R.
- Affiliations
- Vanderbilt University Medical Center (US)
- Lyon 1 Université (FR)
- Cone Health (US)
- Universitair Ziekenhuis Leuven (BE)
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
- University of Utah (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Hospital Universitario de La Princesa (ES)
- University of British Columbia (CA)
- University of California, Los Angeles (US)
- Pliant (United States) (US)
- Pliant Therapeutics, Inc., South San Francisco, California; and
- University of Michigan (US)
- Corresponding author
- Lancaster, Lisa
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-08
- Volume
- 210
- Issue
- 4
- Pages
- 424-434
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC11351797
- OpenAlex
- W4399393072
- Cited by
- 80
- References
- 46
- Citations by year
- 2026: 35 · 2025: 37 · 2024: 8
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
- Funders
- Pliant Therapeutics
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic therapy, treatment-emergent adverse events, safety and tolerability, forced vital capacity decline, fibrosis biomarkers, pirfenidone, nintedanib, dose-dependent effects, diarrhea
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles, Male, Middle Aged, Pyridones, Treatment Outcome, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. https://app.cochat.ai/papers/10.1164/rccm.202403-0636oc
- The paper
- Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., Kim, G. H. J., Jurek, M., Decaris, M., Clark, A., Turner, S., Barnes, C. N., Achneck, H. E., Cosgrove, G. P., Lefebvre, É. A., & Flaherty, K. R. (2024). Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202403-0636oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.